Mineralys Therapeutics
PublicMineralys Therapeutics is now publicly traded
The data on this page reflects Mineralys Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 9, 2023
Last Round
Follow-on Offering
Sep 4, 2025
Total Funding Raised
$786.3M
Company Overview
Mineralys Therapeutics operates in Healthcare and is based in Radnor, Pennsylvania. Its recorded funding history includes a Series B round in June 2022.
Mineralys (NAS: MLYS) is a biopharmaceutical company focused on developing innovative treatments for diseases associated with elevated aldosterone levels, including its lead product candidate, lorundrostat, an oral selective aldosterone synthase inhibitor aimed at managing uncontrolled and resistant hypertension.
Sector
Healthcare
AI Layer
Non-AI
Mineralys Therapeutics Comparables
Compare Mineralys Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Retension Pharmaceuticals | 78% | |
| E-Star BioTech, LLC | 72% | |
| Mandeville Therapeutics | 55% |
For institutional investors. Book with your work email.
Mineralys Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Sep 4, 2025 | ||||
| Private Placement | Feb 8, 2024 | ||||
| IPO | Feb 9, 2023 | ||||
| Series B | Jun 8, 2022 | ||||
| Series A | Apr 6, 2021 |
For institutional investors. Book with your work email.
Mineralys Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Evercore ISI | IPO, Follow-on Offering |
| HealthCor Partners Management | Series B |
| RA Capital Management | IPO, Series B, Private Placement |
| TCG Crossover | Private Placement |
| Guggenheim Securities | IPO |
| Phase4 Partners | Series B |
| Andera Partners | Series B |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_issues_withNov 11, 2026
Mineralys Therapeutics, Inc. reports a widening third-quarter loss in Pennsylvania on Nov 11th '26 as spending on commercial preparations for experimental hypertension drug lorundrostat accelerates ahead of the FDA's Dec. 22nd '26 regulatory decision.
- has_lossNov 5, 2026
Mineralys Therapeutics, Inc. reports a Q3 '26 net loss of $57.3 million, up from $36.9M in Q3 '25, primarily due to higher commercialization-related G&A expenses.
- hiresOct 19, 2026
Mineralys Therapeutics, Inc. appoints Kristine Peterson to its Board of Directors in Pennsylvania on Oct 19th '26, adding her commercial and product launch experience ahead of the potential launch of lorundrostat.
- hiresOct 19, 2026
Mineralys Therapeutics, Inc. appoints Lonnel Coats to its Board of Directors alongside Kristine Peterson in Pennsylvania on Oct 19th '26, adding commercial and product-launch experience ahead of lorundrostat’s potential approval and commercial launch.
- is_developingOct 6, 2026
Mineralys Therapeutics, Inc. extends lorundrostat’s development into early-to-moderate chronic kidney disease and presents Phase 3 Launch-HTN data on blood-pressure and albuminuria reductions at Kidney Week 2026 in Colorado in Oct '26.
For institutional investors. Book with your work email.
Mineralys Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.